Background: As per Ayurveda, Nitya Sevaniya (NS) food items are recommended for daily intake while Nitya Asevaniya (NAS) food items should be avoided for daily intake due to their systemic wholesome and unwholesome effects after consumption, respectively.
Aim and objectives: The present study was conducted to perform in vivo safety evaluation of selected Nitya Sevaniya and Nitya Asevaniya food items.
Materials and methods: Thirty rats were randomly divided into five groups-each containing six Charle’s Foster strain albino rats. Group 1 served as standard diet group, groups 2 and 3 served as test drug received groups namely NS50 and NS100, in which 50% and 100% mixture of Nitya Sevaniya food was administered, respectively. Group 4 and 5 as test drug received groups Nitya Asevaniya 50 (NAS50) and Nitya Asevaniya 100 (NAS100), in which 50% and 100% Nitya Asevaniya food mixtures was administered, respectively. The test diet was administered orally in the form of freshly prepared pellet twice a day ad libitum for 90 days. Parameters studied were gross behavior, body and organ weight, food and water intake, fecal and urine output, hematological and biochemical parameters, electrocardiogram and histology of various organs.
Results: In the NAS100 group, a significant change was observed in 20 of 47 parameters in view of pathological aspect. Among them, three parameters, i.e., platelet count, serum glutamic-oxaloacetic transaminase (SGOT) and indirect bilirubin were above normal limits, while other parameters were within the normal limits. No significant change was observed in any of the parameters in the NS50 and NS100 group after 90 days of administration as compared with the control group.
Conclusion: Considering findings of this study, it is concluded that selected NS food items are safe while consumption of only selected Nitya Asevaniya food items (when administered in 100% dose) for 90 days have the potential of inflammatory changes in the liver, spleen; fat deposition in kidney and impairment of cardiac and renal functions.
Competitive Revenue Strategies in the Medical Consumables Industry: Evidence from Human Resources, Research and Development Expenses and Industry Life Cycle
- This study attempted to explore the competitive advantage strategies of the medical consumables industry (MCI) from the perspectives of human resources, research and development (R&D) and the industry life cycle. As one of the essential branches of modern medical device industry, the MCI has developed rapidly in recent years as global demand for medical consumables has shown continual growth, but it also faces market uncertainty.
- This study took Taiwan’s small/medium medical consumables enterprises (SMMCEs) as a sample, and used the translog revenue function to study the competitive advantage of the MCI through human resource and R&D investment strategies and the stage characteristics of the industry life cycle curve. The results showed that the various human resources and R&D expenses of the small/medium medical consumables industry (SMMCI) can interact with each other to influence total revenue and that the SMMCI needs more varied types of human resources to enhance its competitive advantage.
- The total revenue of the SMMCI decreased as education inputs rose, but it increased along with increases in the number of employee and R&D inputs. Observed from the life cycle curve of the SMMCI, total revenue increased rapidly during the startup and growth stages, increased slowly during the maturity stage, and decreased during the decline stage. Finally, we put forward competitive advantage strategies and management suggestions for medical consumables enterprises (MCEs). We are the first to document the life cycle curve and competitive advantage strategies of the MCI, thereby contributing to the related literature.
[Development of Intelligent Management System for High Value Consumable Material in Operating Room]
Operation room is the most important link for carrying out medical activities in hospital whose demand for medical consumable material is also very large. With the increase of types of consumable material, the process of consumable material management in operating room becomes more complicated, and the traditional management mode can not meet the needs.
In this paper, the technology of Internet of things and artificial intelligence is used to design an intelligent management system of high value consumable material in operating room which improves the efficiency of operation of high value consumable material in operating room, reduces the cost of manpower and improves the safety.
Tissue and Cell Extraction and Purification |
EP10011 |
Neuromics |
100 Tests |
763.2 EUR |
p5 Ligand for Dnak and and DnaJ |
5-01680 |
CHI Scientific |
4 x 5mg |
Ask for price |
Linsmaier and Skoog, With macro- and micronutrients |
CP021-010 |
GenDepot |
10X1L |
121.2 EUR |
Linsmaier and Skoog, With macro- and micronutrients |
CP021-500 |
GenDepot |
50L |
151.2 EUR |
Murashige and Skoog, With Vitamins and Glycine |
CP031-010 |
GenDepot |
10X1L |
118.8 EUR |
Murashige and Skoog, With Vitamins and Glycine |
CP031-500 |
GenDepot |
50L |
151.2 EUR |
p5 Ligand for Dnak and and DnaJ Peptide |
20-abx266082 |
Abbexa |
-
493.20 EUR
-
794.40 EUR
-
376.80 EUR
|
|
Acrolein and Acrylonitrile in Methanol P and T |
603-XM |
Scientific Laboratory Supplies |
1ML |
27.36 EUR |
Testo 175 And 176 temperature And humidity probe |
THE2590 |
Scientific Laboratory Supplies |
EACH |
308.94 EUR |
Murashige and Skoog |
CP023-010 |
GenDepot |
10X1L |
118.8 EUR |
Murashige and Skoog |
CP023-500 |
GenDepot |
50L |
151.2 EUR |
Nitsch and Nitsch |
CP036-010 |
GenDepot |
10X1L |
121.2 EUR |
Nitsch and Nitsch |
CP036-500 |
GenDepot |
50L |
151.2 EUR |
Shenk and Hildebrandt |
CP038-010 |
GenDepot |
10X1L |
121.2 EUR |
Shenk and Hildebrandt |
CP038-500 |
GenDepot |
50L |
151.2 EUR |
Recombinant Human AND |
P0015 |
FN Test |
100ug |
626.83 EUR |
AnD External Display |
BAL2572 |
Scientific Laboratory Supplies |
EACH |
278.16 EUR |
High density larynx and pharynx squamous cell carcinoma and larynx and pharynx tissue array |
LP208 |
TissueArray |
each |
546 EUR |
Mouse Ariway PrimaCell3: Normal Bronchial and and Tracheal Fibroblasts |
2-82003 |
CHI Scientific |
1 Kit |
Ask for price |
Rat Ariway PrimaCell3: Normal Bronchial and and Tracheal Fibroblasts |
2-82503 |
CHI Scientific |
1 Kit |
Ask for price |
Human Airway PrimaCell4: Normal Bronchial and and Tracheal Fibroblasts |
2-96004 |
CHI Scientific |
1 Kit |
Ask for price |
SS grid for size 55 and 75 and HCP50 |
CHA4020 |
Scientific Laboratory Supplies |
EACH |
114 EUR |
Murashige and Skoog, 1/2 Micronutrients and 1/2 Iron |
CP024-010 |
GenDepot |
10X1L |
118.8 EUR |
Murashige and Skoog, 1/2 Micronutrients and 1/2 Iron |
CP024-500 |
GenDepot |
50L |
151.2 EUR |
Be First to Comment